Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations
JCO Precision Oncology · 2024-12 · (8)
DOI: 10.1200/po.24.00240 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCO Precision Oncology, 2024-12. Verfasst von Alessandro Di Federico und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Patients with tumors harboring BRAF class 3 mutations lack targeted therapies. These mutations are characterized by low/absent BRAF kinase domain activation and are believed to amplify already active RAS signaling, potentially triggered by receptor tyrosine kinases like EGFR. MATERIALS AND METHODS Two patients with BRAF class 3–mutated metastatic non–small-cell lung cancer (NSCLC) were treated with erlotinib at our Institution after failure of standard therapies. Two cell lines were established from patients with BRAF class 3–mutated NSCLC, and their sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs) was assessed using EGFR- mutated, BRAF class 1 and 2–mutated, and KRAS -mutated NSCLC cell lines as controls. RESULTS Patient 1, a 60-year-old male with BRAF D594N -mutated NSCLC, achieved complete response to erlotinib after progression on first- and second-line chemotherapy. Patient 2, a 60-year-old female with BRAF D594G -mutated NSCLC, achieved partial response to erlotinib after progression on first-line chemoimmunotherapy. High baseline phosphorylated EGFR values and reduced EGFR activation following erlotinib were observed in BRAF class 3–mutated and EGFR -mutated cell lines, but not in BRAF class 1–mutated, BRAF class 2–mutated, or KRAS -mutated lines. Erlotinib inhibited 2-dimensional growth in BRAF class 3–mutated cell lines (IC 50 6.33 and 7.11 µM) and in the BRAF class 2–mutated cell line (IC 50 5.51 µM), albeit at higher concentrations than in EGFR -mutated lines, whereas it showed no effect on BRAF class 1–mutated (IC 50 , >25 µM) or KRAS -mutated (IC 50 , >25 µM) lines. These findings were corroborated by 3-dimensional and sphere formation assays. In the Cancer Cell Line Encyclopedia, BRAF class 3–mutated NSCLC cell lines showed greater sensitivity to EGFR-TKIs compared with BRAF class 2–mutated and KRAS -mutated lines. CONCLUSION BRAF class 3 mutations in NSCLC may identify a novel targetable population sensitive to EGFR-TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Laboratory of Immunology and Biology of Metastasis, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
ORCID-Profile: Alessandro Di Federico, Stefania Angelicola, Francesca Ruzzi, Maria Sofia Semprini, Hugo De Jonge, Andrea De Giglio, Francesca Sperandi, Stefano Brocchi, Francesca Giunchi, Elisa Gruppioni, Annalisa Altimari, Pier-Luigi Lollini, Arianna Palladini, Francesco Gelsomino
Zitieren
APA
Di Federico, A., Angelicola, S., Frascino, M., Siracusa, I., Bisanti, B., Ruzzi, F., Semprini, M. S., De Jonge, H., De Giglio, A., Sperandi, F., Brocchi, S., Melotti, B., Giunchi, F., Gruppioni, E., Altimari, A., Lollini, P. L., Ardizzoni, A., Palladini, A., & Gelsomino, F. (2024). Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations. JCO Precision Oncology. https://doi.org/10.1200/po.24.00240
Vancouver
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, et al. Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations. JCO Precision Oncology. 2024. doi:10.1200/po.24.00240
BibTeX
@article{DiFederico2024,
author = {Di Federico, Alessandro and Angelicola, Stefania and Frascino, Mariateresa and Siracusa, Irene and Bisanti, Beatrice and Ruzzi, Francesca and Semprini, Maria Sofia and De Jonge, Hugo and De Giglio, Andrea and Sperandi, Francesca and Brocchi, Stefano and Melotti, Barbara and Giunchi, Francesca and Gruppioni, Elisa and Altimari, Annalisa and Lollini, Pier-Luigi and Ardizzoni, Andrea and Palladini, Arianna and Gelsomino, Francesco},
title = {Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.24.00240}
}
EUVIMED